MedChemExpress LLC (MCE)

MedChemExpressModel Gemtuzumab ozogamicin -220578-59-6

SHARE
Gemtuzumab ozogamicin is an antibody-drug conjugate (ADC) consisting of a humanized immunoglobulin (IgG4) antibody directed against CD33 that is conjugated to the cytotoxic agent Calicheamicin (HY-19609). Calicheamicin is a cytotoxic antibiotic. Gemtuzumab ozogamicin can be used for the research of acute myeloid leukemia (AML)[1][2].
Most popular related searches

MCE products for research use only. We do not sell to patients.

Gemtuzumab ozogamicin

MCE China:Gemtuzumab ozogamicin

Brand:MedChemExpress (MCE)

Cat. No.HY-109539

CAS:220578-59-6

Purity:98.0%

Storage:-80°C, protect from light

Shipping:Shipping with dry ice.

Description:Gemtuzumab ozogamicin is an antibody-drug conjugate (ADC) consisting of a humanized immunoglobulin (IgG4) antibody directed against CD33 that is conjugated to the cytotoxic agent Calicheamicin (HY-19609). Calicheamicin is a cytotoxic antibiotic. Gemtuzumab ozogamicin can be used for the research of acute myeloid leukemia (AML).

In Vitro:Gemtuzumab ozogamicin (1-250 ng/mL ; 72 hours) has cell cytotoxicity in CD33-positive cells[1]. Gemtuzumab ozogamicin is an ADC. After binding of the antibody to CD33 and subsequent internalization, Calicheamicin mediates cytotoxicity to CD33-positive myeloid cells primarily through induction of DNA damage and subsequent apoptosis[1].

Hot selling product:Ixazomib citrate  | Dipyridamole  | Vorasidenib  | GSK2334470  | Erythromycin  | GSK621  | Mulberroside A  | BCI  | PEG2000-DSPE  | Lichenase

Trending products:Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides

References:

[1]. Yi Liu, et al. CD33-directed immunotherapy with third-generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and CD33-edited acute myeloid leukemia and hematopoietic stem and progenitor cells. Int J Cancer. 2022 Apr 1;150(7):1141-1155.  [Content Brief]

[2]. Baron J, et al. Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia. Expert Rev Clin Pharmacol. 2018;11(6):549-559.  [Content Brief]

Brand introduction:
•   MCE (MedChemExpress) has a global exclusive compound library of more than 200 kinds, and we are committed to providing the most comprehensive range of high-quality small molecule active compounds for scientific research customers around the world;
•   More than 50,000 highly selective inhibitors and agonists are involved in various popular signaling pathways and disease areas;
•   The products cover a variety of recombinant proteins, peptides, commonly used kits, more PROTAC, ADC and other characteristic products, widely used in new drug research and development, life science and other scientific research projects;
•   Provide virtual screening, ion channel screening, metabolomics analysis detection analysis, drug screening and other professional technical services;
•   It has a professional experimental center and strict quality control and verification system;
•   Provide LC/MS, NMR, HPLC, chiral analysis, elemental analysis and other quality inspection reports to ensure the high purity and high quality of products;
•   The biological activity of the products has been verified by the experiments of customers in various countries;
•   A variety of top journals such as Nature, Cell, Science and pharmaceutical patents have included the scientific research results of MCE customers;
•   Our professional team tracks the latest pharmaceutical and life science research and provides you with the latest active compounds in the world;
•   It has established long-term cooperation with the world's major pharmaceutical companies and well-known scientific research institutions。